Plain-English translation of NCT06428019 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing , a medication that works by helping the body's immune system fight chronic lymphocytic leukemia (CLL), a common blood cancer. Researchers want to find the safest way to start this medication when combined with one of two other drugs. The study focuses on preventing a serious side effect called tumor lysis syndrome, which can happen when cancer cells die too quickly.
CLL is the most common type of leukemia, and while this medication combination shows promise, doctors want to understand the best way to introduce it gradually to keep patients safe and prevent dangerous complications.
You likely qualify if…
You likely don't qualify if…
You will be assigned to one of four treatment groups and receive the study medications by mouth or intravenously, with the dose of increased gradually over different time periods depending on your group. You'll attend regular clinic visits over approximately 28 months for blood tests, medical exams, and check-ups to monitor how well the treatment is working and watch for side effects. The study involves more frequent visits than standard care, but it allows doctors to catch any problems early and adjust your treatment as needed.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States